ライフサイエンスコーパス: platelet adhesion

1 nd thrombosis, in part, by supporting stable platelet adhesion.

2 ing events are crucial for the initiation of platelet adhesion.

3 e the ability to significantly reduce static platelet adhesion.

4 elet aggregation and beta1 integrin-mediated platelet adhesion.

5 a receptor other than GPIbalpha can mediate platelet adhesion.

6 lted in the loss of alpha(IIb)beta3-mediated platelet adhesion.

7 hat could serve as a driving force for tight platelet adhesion.

8 nt ligand resulted in a greater stability in platelet adhesion.

9 role of circulating VWF in the initiation of platelet adhesion.

10 VWF multimers that, as a result, can mediate platelet adhesion.

11 < .05 vs wild-type), but not in the initial platelet adhesion.

12 the manifestation of functional activity in platelet adhesion.

13 bind to von Willebrand factor, resulting in platelet adhesion.

14 -coated substrates to examine flow-dependent platelet adhesion.

15 lusters, even in the absence of any platelet-platelet adhesion.

16 von Willebrand factor multimers could reduce platelet adhesion.

17 s show normal bleeding times despite reduced platelet adhesion.

18 ne cytoskeleton and for the stabilization of platelet adhesion.

19 f LIMK1(-/-) platelets in VWF-induced stable platelet adhesion.

20 as observed using fluorescence imaging, and platelet adhesion (81.7 +/- 2.5%) in vitro over a 2 h pe

21 uced protein absorption (64.7% decrease) and platelet adhesion (85.6% decrease) compared to bare PCL

22 ng cleavage by ADAMTS13, may promote initial platelet adhesion above glomerular endothelial cells.

23 transmitted cellular forces are critical for platelet adhesion, activation, aggregation and contracti

24 Platelet adhesion, activation, and aggregation at sites

25 The role of platelet adhesion, activation, and aggregation in acute

26 NETs perfused with blood caused platelet adhesion, activation, and aggregation.

27 multimeric plasma glycoprotein that mediates platelet adhesion, activation, and aggregation.

28 involved in several key steps of thrombosis: platelet adhesion/activation, thrombus growth, and stabi

29 a1 in their alpha-granules and release it on platelet adhesion/activation.

30 the relationship between RBC hematocrit and platelet adhesion activity.

31 VWF and ADAMTS13 are major determinants of platelet adhesion after vessel injury.

32 CXCL16-induced stimulation of platelet adhesion again was prevented by phosphatidylino

33 nteracts with CLEC-2 on platelets, mediating platelet adhesion, aggregation, and secretion to guide t

34 cidating the molecular mechanisms leading to platelet adhesion, aggregation, shape change, and secret

35 lation in a dose-dependent manner as well as platelet adhesion, although total plaque area was reduce

36 nin-211 (alpha2beta1gamma1), allow efficient platelet adhesion and activation across a wide range of

37 Whether vascular laminins support platelet adhesion and activation and the significance of

38 nti-GP VI antibody completely inhibited both platelet adhesion and activation of the GP IIb-IIIa comp

39 t aggregation and activation studies reduced platelet adhesion and activation partially.

40 eatment with MMP inhibitors partly prevented platelet adhesion and activation, as well as vWF express

41 coating prevents fibrin attachment, reduces platelet adhesion and activation, suppresses biofilm for

42 , functions during blood clotting to promote platelet adhesion and activation.

43 tor (VWF), glycoprotein (GP) Ib-IX, mediates platelet adhesion and activation.

44 ), glycoprotein (GP) Ib-IX, mediates initial platelet adhesion and activation.

45 ycoprotein Ib-IX (GPIb-IX), mediates initial platelet adhesion and activation.

46 nded periods of time (> 20 h) while reducing platelet adhesion and activation.

47 roles of alpha2beta1 and GPVI in supporting platelet adhesion and aggregate formation on collagen at

48 m the basis of a unifying two-state model of platelet adhesion and aggregate formation on collagen th

49 ation of nitric oxide synthase (NOS), limits platelet adhesion and aggregation after a prothrombotic

50 is a plasma metalloproteinase that regulates platelet adhesion and aggregation by cleaving ultra-larg

51 Integrins are critical for platelet adhesion and aggregation during arterial thromb

52 lular matrices (ECMs) that are essential for platelet adhesion and aggregation during hemo stasis and

53 Platelet adhesion and aggregation enable a haemostatic p

54 and unbinding that underlie the dynamics of platelet adhesion and aggregation in blood flow.

55 Recombinant ADAMTS13 reduced platelet adhesion and aggregation in histamine-activated

56 Platelet adhesion and aggregation play a critical role i

57 onary syndromes aim toward limiting platelet-platelet adhesion and aggregation processes.

58 Platelet adhesion and aggregation to the angioplasty sit

59 In spite of these functional defects, platelet adhesion and aggregation were better supported

60 However, platelet adhesion and aggregation were reduced in vitro

61 ves von Willebrand factor multimers, reduces platelet adhesion and aggregation, and downregulates thr

62 BSA coating of thrombogenic surfaces reduces platelet adhesion and aggregation, possibly by increasin

63 rand's factor receptor complex that mediates platelet adhesion and aggregation.

64 sis and thrombosis because they mediate both platelet adhesion and aggregation.

65 r signaling events that contribute to stable platelet adhesion and aggregation.

66 selectin, which induce leukocyte rolling and platelet adhesion and aggregation.

67 lfatides as a major ligand for P-selectin in platelet adhesion and aggregation.

68 e in physiological processes associated with platelet adhesion and aggregation.

69 (3) is the fibrinogen receptor that mediates platelet adhesion and aggregation.

70 n (Fg), the two key ligands known to mediate platelet adhesion and aggregation.

71 fields that have revealed new mechanisms of platelet adhesion and aggregation.

72 derlying the dynamics of fibrinogen-mediated platelet adhesion and aggregation.

73 t with an inhibitory role for supervillin in platelet adhesion and arterial thrombosis.

74 (Fn1(syn/syn)) suffer from surprisingly mild platelet adhesion and bleeding defects due to delayed th

75 binding site for alpha(IIb)beta3 involved in platelet adhesion and clot retraction and define the new

76 eptides duplicating these segments inhibited platelet adhesion and clot retraction but not platelet a

77 Combined blockade of leukocyte/platelet adhesion and coagulation may provide convincing

78 we show that the physical interplay between platelet adhesion and hemodynamics in a microchannel man

79 nd factor (VWF) to GP Ib-IX mediates initial platelet adhesion and increases the subsequent adhesive

80 ptor, glycoprotein Ib-IX (GPIb-IX), mediates platelet adhesion and induces signaling leading to integ

81 ycoprotein Ibalpha (GPIbalpha) promotes both platelet adhesion and inflammatory actions of platelets

82 le in hemostasis and thrombosis by mediating platelet adhesion and platelet aggregation.

83 nteractions with P-selectin are important in platelet adhesion and platelet aggregation.

84 c binding site for alphaIIbbeta3 involved in platelet adhesion and platelet-mediated fibrin clot retr

85 X-V complex within rafts is crucial for both platelet adhesion and postadhesion signaling.

86 decipher mechanisms of A1-GPIbalpha-mediated platelet adhesion and resolve dynamic secondary structur

87 show that, in fact, both PS and PE influence platelet adhesion and secretion.

88 nd shear microfluidic assays, Slit2 impaired platelet adhesion and spreading on diverse extracellular

89 ted the ILK-PINCH-Parvin complex and altered platelet adhesion and spreading.

90 d may play important roles in the process of platelet adhesion and spreading.

91 asing substrate stiffness leads to increased platelet adhesion and spreading.

92 Unexpectedly, free Hb also promoted firm platelet adhesion and stable microthrombi on VWF.

93 n (nominal values) tensions generated during platelet adhesion and tensions above 54 piconewton gener

94 d by their ability to support flow-dependent platelet adhesion and their ability to inhibit ristoceti

95 endothelial collagen acts as a substrate for platelet adhesion and thrombus formation after vascular

96 High shear force critically regulates platelet adhesion and thrombus formation during ischemic

97 that vWF plays a critical role in mediating platelet adhesion and thrombus formation following mesen

98 ne deficiency significantly accelerates both platelet adhesion and thrombus formation in mice followi

99 von Willebrand factor (vWF) mediates platelet adhesion and thrombus formation via its interac

100 wed that nanofibrous scaffolds alone induced platelet adhesion and thrombus formation, which was supp

101 articularly collagen, play a pivotal role in platelet adhesion and thrombus formation.

102 of integrin alphaIIbbeta3 to support stable platelet adhesion and thrombus formation.

103 ), glycoprotein (GP) Ib-IX, mediates initial platelet adhesion and transmits signals leading to plate

104 Furthermore, P3 supported platelet adhesion and was an effective inhibitor of plat

105 kindlin-3 was introduced into HEL cells and platelets; adhesion and spreading of both cell types wer

106 ltimers adhere to endothelial cells, support platelet adhesion, and may induce microvascular thrombos

107 Free Hb (>/=50 mg/dL) effectively augmented platelet adhesion, and microthrombi formation on fibrin(

108 sion of the platelet receptor vWF, increased platelet adhesion, and platelet activation.

109 vities, including factor XIIIa crosslinking, platelet adhesion, and platelet-mediated clot retraction

110 PS was enriched dramatically and decreased platelet adhesion as well as secretion from delta-, alph

111 ks VWFpp binding to VWF-D'D3, also abrogated platelet adhesion, as shown by shear-induced platelet ag

112 recombinant VWFpp in both flow-chamber-based platelet adhesion assays and viscometer-based shear-indu

113 Versican facilitates platelet adhesion at low shear and cooperates with colla

114 e in hemostasis and thrombosis by initiating platelet adhesion at sites of arterial injury through in

115 Platelet adhesion at sites of vascular injury is mediate

116 (VWF) is a multimeric protein that mediates platelet adhesion at sites of vascular injury, and ADAMT

117 d from vascular endothelial cells, initiates platelet adhesion at sites of vascular injury.

118 echanism, ADAMTS13 activity might compromise platelet adhesion at sites of vascular injury.

119 -selectin expression, VCAM-1 expression, and platelet adhesion between 30 and 40 weeks of age.

120 coprotein Ib-IX-V complex, not only mediates platelet adhesion but also transmits signals leading to

121 nce of endothelial cells in stenoses reduces platelet adhesion but increases sickle cell disease (SCD

122 -111 (alpha1beta1gamma1) is known to support platelet adhesion but is absent from most blood vessels,

123 tirofiban (anti-GPIIb/IIIa) did not prevent platelet adhesion but nearly eliminated the deposition o

124 deficiency of pFN did not affect the initial platelet adhesion, but a delay of several minutes in thr

125 is a multidomain metalloprotease that limits platelet adhesion by a feedback mechanism in which fluid

126 gands may promote the feedback inhibition of platelet adhesion by stimulating the cleavage of domain

127 tween the thrombin and collagen receptors in platelet adhesion by utilizing a collagen-related peptid

128 Too little platelet adhesion causes bleeding that is typical of von

129 tigate the effect of a drug known to inhibit platelet adhesion (clopidogrel) and, in the presence of

130 cant reductions in I/R-induced leukocyte and platelet adhesion compared with wild-type mice exposed t

131 M: 146.2 +/- 20.4 min, p < 0.05) and reduced platelet adhesion, complement activation, coagulation ac

132 brinogen binding to alpha(IIb)beta(3) during platelet adhesion decreased integrin-associated PP2A act

133 balpha) and genetically engineered mice with platelet adhesion defects, we investigated the role of p

134 daptor absent in patients with leukocyte and platelet adhesion deficiency syndrome and is critical fo

135 y of von Willebrand factor (VWF) to initiate platelet adhesion depends on the number of monomers in i

136 F in plasma of patients with ALI/ALF support platelet adhesion, despite a relative loss of function o

137 ogrel) and, in the presence of the drug, the platelet adhesion due to activation by 5.00 microM ADP d

138 in long string-like structures that initiate platelet adhesion during hemostasis and thrombosis.

139 intracellular binding partners, anchors the platelet adhesion glycoprotein (GP) Ib-IX-V receptor to

140 t glycoprotein Ibalpha that supports initial platelet adhesion in absence of von Willebrand factor (V

141 d P-selectin and its contribution to PMN and platelet adhesion in hepatic damage.

142 iolar vasodilation and venular leukocyte and platelet adhesion in mice after injection with either mo

143 uggesting that TSP1 does not mediate initial platelet adhesion in the absence of VWF.

144 -induced thrombosis model, we report similar platelet adhesion in Tsp1(-/-)/Vwf(-/-) mice compared wi

145 A NPs have also proven capable of inhibiting platelet adhesion in vitro with a reduced IC50 of 1.83 +

146 In addition, MSCs, as ECs, resisted platelet adhesion in vitro, which depended on cell-surfa

147 in a ristocetin cofactor ELISA and increased platelet adhesion in whole blood to collagen under arter

148 ha(IIb)beta(3) by immobilized ligands during platelet adhesion induces a transmembrane conformation c

149 Platelet adhesion is an essential function in response t

150 The enhanced alpha(2)beta(1)-mediated platelet adhesion is controlled by phospholipase C (PLC)

151 cal importance of rapid bond dissociation in platelet adhesion is demonstrated by kinetic characteriz

152 Thus, GPIb-IX-dependent platelet adhesion is doubly controlled by vWF conformati

153 cally in a number of settings such as during platelet adhesion, leukocyte trans-migration, and angiog

154 of von Willebrand disease, whereas too much platelet adhesion may cause thrombotic thrombocytopenic

155 Ibalpha, thrombin could potentially act as a platelet adhesion molecule or receptor dimerisation trig

156 To examine the role of the platelet adhesion molecule von Willebrand factor (vWf) i

157 f platelets with blocking antibodies against platelet adhesion molecules did not alter their effect o

158 focused solely on recapitulating aspects of platelet adhesion; more complex platelet behaviours such

159 pite the presence of arterial shear, delayed platelet adhesion occurred and stable thrombi formed.

160 a is not critical for integrin activation or platelet adhesion on collagen.

161 istent with the known lack of shear-enhanced platelet adhesion on fibrinogen-coated surfaces.

162 on by NO of alphaIIb/beta3 integrin-mediated platelet adhesion on immobilized fibrinogen, mediated in

163 ibited platelet aggregation while preserving platelet adhesion on plaque.

164 Effects of inhibiting platelet adhesion on SEC apoptosis was tested using sial

165 Although the biology of platelet adhesion on subendothelial matrix after vascula

166 or glycoprotein VI and strongly affects firm platelet adhesion on von Willebrand factor (VWF) under a

167 k has been shown between these receptors and platelet adhesion or NO production.

168 ew NO-release coating exhibit no significant platelet adhesion or thrombus formation, but control sen

169 ferences were found in either initial single-platelet adhesion or thrombus volume.

170 Platelet adhesion (P<0.01) and activation (P=0.03) on PV

171 shared with those elicited by the inhibitory platelet adhesion receptor PECAM-1 (platelet endothelial

172 an polymorphism in the Kozak sequence of the platelet adhesion receptor, glycoprotein (GP) Ibalpha, a

173 Moreover, targeting another platelet adhesion receptor, glycoprotein IIb/IIIa (GPIIb

174 ty due to molecular abnormalities in a major platelet adhesion receptor, integrin alphaIIbbeta3.

175 The platelet adhesion receptor, the glycoprotein Ib-IX-V com

176 dhesion defects, we investigated the role of platelet adhesion receptors in stabilizing tumor vessels

177 r injury in that it does not depend on major platelet adhesion receptors or GPCR signaling.

178 in genetically engineered mice lacking major platelet adhesion receptors or their activators (alphaII

179 into thrombi is mediated by interactions of platelet adhesion receptors with ligands on the injured

180 ntibody M3/38) or collagen receptor-mediated platelet adhesion (revacept, a dimeric platelet collagen

181 f the immunoglobulin superfamily involved in platelet adhesion, secretion and aggregation.

182 sduce those cues into differential levels of platelet adhesion, spreading, and activation provides bi

183 tivity mediate substrate stiffness-dependent platelet adhesion, spreading, and activation to differen

184 15N-1H NMR and platelet adhesion studies show that the peptide heterotr

185 shear stress conditions effectively blocked platelet adhesion, suggesting that the initial interacti

186 In vitro platelet adhesion tests indicate that the xerogel coatin

187 The second is an F11R-mediated platelet adhesion that is not dependent on either the Fc

188 to lowering lipids, statins favorably affect platelet adhesion, thrombosis, endothelial function, inf

189 injury, von Willebrand factor (VWF) mediates platelet adhesion through binding to platelet glycoprote

190 A molecule identified as critical for platelet adhesion to a cytokine-inflamed endothelial sur

191 ing high-affinity GPIbalpha binding and firm platelet adhesion to a partially disordered A1 domain.

192 mechanism for the regulation of rheological platelet adhesion to A1 based on cooperative flexibility

193 We demonstrate that platelet adhesion to alpha2-CRP is substantially enhance

194 -coupled receptors (GPCRs) produces enhanced platelet adhesion to alpha2-CRP.

195 al microscopy revealed a >3-fold increase in platelet adhesion to angiogenic vessels of Matrigel comp

196 alpha may alter the mechanical regulation of platelet adhesion to cause hemostatic defects as found i

197 activation of the GP IIb-IIIa complex after platelet adhesion to collagen and generation of thrombox

198 m-Fab-F inhibits both GPVI-dependent static platelet adhesion to collagen and thrombus formation on

199 tivation were confirmed in vitro by studying platelet adhesion to collagen in flow conditions, integr

200 ficient beta1 integrin show strongly reduced platelet adhesion to collagen in vitro and in a carotis

201 GxO/SGER peptides inhibited platelet adhesion to collagen monomers with order of pot

202 egrin alpha2beta1 play significant roles for platelet adhesion to collagen under flow and that the lo

203 nder static conditions and completely blocks platelet adhesion to collagen under flow conditions at h

204 genetic approaches to study human and mouse platelet adhesion to collagen under flow conditions.

205 elet activation, a requirement for efficient platelet adhesion to collagen under flow.

206 eceptor density results in severe defects in platelet adhesion to collagen under flow.

207 activation of T cells (LAT) is critical for platelet adhesion to collagen under flow.

208 Platelet adhesion to collagen via collagen receptors is

209 2 beta 1 integrin is a critical mediator of platelet adhesion to collagen within the vessel wall aft

210 ptor, glycoprotein VI (GPVI) and its role in platelet adhesion to collagens.

211 In contrast, thrombin-stimulated platelet adhesion to cultured human umbilical vein endot

212 Platelet adhesion to dA1VWF induced Src kinase-dependent

213 ace-bound von Willebrand factor and supports platelet adhesion to damaged vascular surfaces.

214 ha) to von Willebrand factor (VWF) initiates platelet adhesion to disrupted vascular surface under ar

215 CXCL16 enhanced platelet adhesion to endothelium in vitro after high art

216 , we found that ADAMTS13 down-regulates both platelet adhesion to exposed subendothelium and thrombus

217 The von Willebrand factor (vWF) mediates platelet adhesion to exposed subendothelium at sites of

218 Platelet adhesion to ferric chloride-treated mesenteric

219 This Fab also reduced platelet adhesion to fibrin at low (300 s(-1)) and high

220 we studied the effect of hemoglobin (Hb) on platelet adhesion to fibrin(ogen) under conditions of di

221 both alphav beta3 and alphaIIb beta3 mediate platelet adhesion to fibrin.

222 demonstrate this technique by measurement of platelet adhesion to fibrinogen as a means to quantify t

223 Platelet adhesion to fibrinogen caused a rapid increase

224 t adhesion and was an effective inhibitor of platelet adhesion to fibrinogen fragments.

225 Moreover, platelet adhesion to fibrinogen stimulates actin rearran

226 Platelet adhesion to fibrinogen through integrin alpha(I

227 trated that alphaIIb beta3 integrin mediates platelet adhesion to fibrinogen, whereas both alphav bet

228 Platelet adhesion to hepatic sinusoidal endothelial cell

229 Upon platelet adhesion to immobilized Fg, CIB localizes to th

230 , Y731 and Y774 undergo phosphorylation upon platelet adhesion to immobilized fibrinogen, which was i

231 e-rich repeat (LRR) protein family, mediates platelet adhesion to immobilized von Willebrand factor (

232 in the function of endothelial cells and in platelet adhesion to inflamed endothelium.

233 ) with von Willebrand factor (VWF) initiates platelet adhesion to injured vascular wall to stop bleed

234 Ibalpha and von Willebrand factor initiates platelet adhesion to injured vessel walls, and the adhes

235 e blood von Willebrand factor (VWF) mediates platelet adhesion to injured vessels by sequestering pla

236 (GPIbalpha) binding to vWF, which initiates platelet adhesion to injured vessels.

237 the avidity of thrombin- and ADP-stimulated platelet adhesion to intact or thrombin-cleaved human os

238 APC prior to induction of NETosis inhibited platelet adhesion to NETs.

239 intravascular inflammatory events, including platelet adhesion to neutrophils, an important event in

240 mediated adhesion, L-selectin expression, or platelet adhesion to neutrophils, suggesting that cytosk

241 Furthermore, they indicate that platelet adhesion to osteopontin-coated surfaces require

242 and elicited anti-pig antibodies, recipient platelet adhesion to pig hematopietic progenitor cells,

243 Src family and Syk tyrosine kinases promotes platelet adhesion to primary mouse lymphatic endothelial

244 e glycoprotein (GP) Ib-IX-V complex mediates platelet adhesion to reactive substrates under high shea

245 phenotypical range of bleeding from lack of platelet adhesion to severe thrombocytopenia.

246 is a multimeric plasma protein that mediates platelet adhesion to sites of vascular injury.

247 VWF is required for platelet adhesion to sites of vessel injury, a process v

248 In addition, aegyptin attenuates platelet adhesion to soluble or fibrillar collagen.

249 nt of the GP Ib-IX-V complex, which mediates platelet adhesion to subendothelium at sites of injury.

250 e show that in ferric chloride-injured veins platelet adhesion to subendothelium is decreased and thr

251 1 EMI domain (GST-EMI) competitively reduced platelet adhesion to surface-coated PEAR1, diminished pl

252 To determine whether platelet adhesion to surfaces coated with the matrix pro

253 gs support the hypothesis that inhibition of platelet adhesion to the brain microvasculature protects

254 oprotein ligand 1 axis, followed by (2) firm platelet adhesion to the endothelium via interaction of

255 e (NO) production, a recognized inhibitor of platelet adhesion to the endothelium, increased the numb

256 Platelet adhesion to the extracorporeal circuits was sig

257 optimization studies, and studies involving platelet adhesion to the immobilized endothelium, were p

258 Weibel-Palade bodies (WPBs) is required for platelet adhesion to the injured vessel wall.

259 Cs to participate in thrombosis by mediating platelet adhesion to the intact endothelial surface.

260 were implicated in recognition of P3, since platelet adhesion to the peptide was blocked by function

261 efined incubation time quantitatively assays platelet adhesion to the protein matrix.

262 s interaction may play a significant role in platelet adhesion to the site of endothelial injury.

263 monstrating the role of P2Y(12) in mediating platelet adhesion to thrombogenic surfaces (collagen, vo

264 In this respect, therefore, platelet adhesion to vascular wall structures, to one an

265 Platelet adhesion to von Willebrand factor (VWF) activat

266 complex plays a critical role in initiating platelet adhesion to von Willebrand factor (vWF) at the

267 ural integrity to the plasma membrane during platelet adhesion to von Willebrand factor (VWF) under h

268 bocytopenia, shedding of GPIbalpha, impaired platelet adhesion to von Willebrand factor, and inabilit

269 mutation, Gly233Val, promotes and stabilizes platelet adhesion to VWF at shear rates that do not supp

270 Platelet adhesion to VWF fibers was reduced in proportio

271 The A1 domain, responsible for platelet adhesion to VWF in hemostasis, unfolds through

272 2 modulators, ristocetin and botrocetin, and platelet adhesion to VWF surfaces under flow.

273 kout platelets were also defective in stable platelet adhesion to VWF under shear stress that is inde

274 Platelet adhesion to vWF was impaired in P2Y12-/- platel

275 tes of A1 takes precedence and drives normal platelet adhesion to VWF.

276 Platelet adhesion to wild-type (WT) A1A2A3 protein, coll

277 In platelets, adhesion to fibrinogen stimulated the associa

278 ucidate the mechanism of thrombus growth and platelet adhesion under conditions of arterial shear rat

279 ed VWF binding to platelets and VWF-mediated platelet adhesion under flow conditions.

280 ons were tested for their ability to mediate platelet adhesion under flow.

281 licular system) that results in dysregulated platelet adhesion under haemodynamic shear stress.

282 latelet activation as well as CXCL16-induced platelet adhesion under high arterial shear stress in vi

283 be that platelet vimentin engages VWF during platelet adhesion under high shear stress.

284 ns that differentially alter the strength of platelet adhesion under shear flow.

285 sis, second-messenger production, and stable platelet adhesion under shear in vivo.

286 In both cases, we find that the rate of platelet adhesion varies greatly with the RBC hematocrit

287 ing stimulation with cytokines and following platelet adhesion via P-selectin.

288 or PI3KC2alpha in regulating shear-dependent platelet adhesion via regulation of membrane structure,

289 Besides promoting platelet adhesion, VWF carries Factor VIII.

290 cificity of Cyr61- and Fisp12/mCTGF-mediated platelet adhesion was demonstrated by specific inhibitio

291 nhibition and 5.00 microM ADP, the affect on platelet adhesion was further increased to 127 +/- 5.2.

292 Platelet adhesion was not abolished in beta3-deficient m

293 I [CalDAG-GEFI]), thus indicating that firm platelet adhesion was not necessary for their supporting

294 RBC-platelet adhesion was reduced in half by antibodies agai

295 heir inhibitory effects on GPIb-IX-dependent platelet adhesion were reversed by exogenous cGMP.

296 hrough GPIbalpha are involved in maintaining platelet adhesion when external forces are absent.

297 sclerosis reduces endothelial activation and platelet adhesion, which are likely responsible for the

298 o the surface of biomaterial correlates with platelet adhesion, which is mediated by von Willebrand f

299 e of Weibel-Palade bodies, induced immediate platelet adhesion (within 15 seconds) and translocation

300 endorepellin supported alpha2beta1-dependent platelet adhesion, without appreciably activating or agg